-
Hengrui and Heyi won the first imitation of ophthalmic drugs, and 7 exclusive evaluation varieties are eye-catching!
Time of Update: 2022-09-06
0 China Drug Review DatabaseSince the beginning of this year, 5 ophthalmic drugs (15 product specifications) have been approved, and the diquaphososoline sodium eye drops of Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Pharmaceutical, and the lidocaine hydrochloride eye gel of Sichuan Heyi Pharmaceutical are the first in China.
-
A number of domestic pharmaceutical companies accelerate the deployment of rare disease drugs to win market opportunities
Time of Update: 2022-09-06
The industry said that with the help of favorable policies, drugs for rare diseases will be launched at an accelerated pace, and domestic companies have also begun to pay attention to the field of rare diseases, deploying research and development to win market opportunities .
-
The high-level turnover of pharmaceutical companies is frequent, and changes under the medical reform may continue
Time of Update: 2022-09-06
[Pharmaceutical Network Industry News] Recently, AstraZeneca announced that it has appointed Liu Ming as Vice President of AstraZeneca China, Head of the Lung Cancer Treatment and Tumor Immunotherapy-related Business Units of the Oncology Division, and joined the Chinese management team to directly report to AstraZeneca.
-
How did the listed pharmaceutical companies perform in the fifth set of standards on the Science and Technology Innovation Board in the first half of the year?
Time of Update: 2022-09-06
The announcement shows that the company's second-line treatment indications for fumetinib have been approved for marketing in March 2021, and it was included in the national medical insurance list that year, and the product has been in high volume .
-
Getting rid of the traditional manufacturing business model, pharmaceutical machine companies are accelerating their development towards diversification
Time of Update: 2022-09-06
11%; realized a net profit of 403 million yuan attributable to shareholders of listed companies, a year-on-year increase of 18.
11%; realized a net profit of 403 million yuan attributable to shareholders of listed companies, a year-on-year increase of 18.
-
Performance soared 539.5%! Backed by 6 billion varieties, the myth of the resurgence of Eastern Sunshine Medicine?
Time of Update: 2022-09-06
Figure 1 Sales of oseltamivir in domestic public medical institutions of Eastern Sunshine Medicine After the outbreak of new crown pneumonia, with the substantial promotion of epidemic prevention measures such as wearing masks, the number of influenza patients around the world has dropped sharply, and influenza drugs, including Dongguang Medicine Kewei, have encountered a "cold wave" in the market.
-
Drug safety has attracted much attention, and quality supervision and sampling inspections are becoming more frequent
Time of Update: 2022-09-06
It is understood that since the beginning of this year, in order to strengthen the supervision of drug quality and ensure the safety of public medication, many places have also launched supervision and inspection of drug production, operation, and use units, and issued announcements .
-
Multi-pharmaceutical companies said: innovative drugs began to contribute to performance and realize value realization
Time of Update: 2022-09-06
Innovative drugs have begun to contribute to performance (Source: Pharmaceutical Network) For example, Kelun Pharmaceutical stated in its mid-year report that in addition to the large volume of generic drugs, the company has also ushered in a new growth point, that is, innovative drug research and development has begun to contribute revenue .
-
Special rectification of traditional Chinese medicine pieces is being carried out in many places!
Time of Update: 2022-09-06
It is reported that in order to further rectify the production and operation order of Chinese herbal decoction pieces, improve the quality of Chinese medicine decoction pieces, and effectively ensure the safety of the masses, the Health and Health Bureau of Yongding District, Zhangjiajie, in conjunction with the Municipal Health and Health Commission, inspected the feedback problems in the traditional Chinese medicine decoction pieces in the district in mid-August.
-
Just after the opening of September, the executive of this pharmaceutical company left!
Time of Update: 2022-09-06
Companies are looking for new high-growth businesses Companies are looking for new high-growth businesses The industry pointed out that Zhonghong Medical belongs to the A-share glove concept stock, before 2019, the company's attributable net profit was less than 100 million, with the change of the environment, the global demand for medical protection products increased, gloves brought performance explosion to the company, from 2020 to 2021, the company achieved attributable net profit of more than 2 billion yuan.
-
The grand opening of the 2022 service trade fair The topic of health and health services has attracted attention
Time of Update: 2022-09-06
In 2022, the high-profile international event China International Fair for Trade in Services (hereinafter referred to as the "Service Trade Fair") kicked off in Beijing. In 2022, the high-profile int
-
Seven pharmaceutical companies released their semi-annual results on the same day, with some companies increasing their net profit by over 600%!
Time of Update: 2022-09-06
53% year-on-year The 2022 semi-annual report released by Xingqi Eye Medicine shows that during the reporting period, the company achieved operating income of 601 million yuan, a year-on-year increase of 29.
-
New regulations on centralized procurement of proprietary Chinese medicines!
Time of Update: 2022-09-06
In terms of supervision, for medical institutions with serious delays in work progress and obvious abnormality in purchase quantity and purchase amount, measures such as interviews, letter inquiries, suspension of refusal to pay medical insurance settlement funds, and corresponding deduction of annual medical insurance reservations will be taken as appropriate to punish medical institutions.
-
10 billion cold proprietary Chinese medicine market! 16 products over 100 million were exposed
Time of Update: 2022-09-06
From the perspective of TOP20, 16 products have sold more than 100 million, 6 exclusive varieties have been listed, and the cold spirit granules of China Resources Sanjiu have won the "pin crown"; Four brands, including China Resources Laotongjun's antiviral oral liquid, Shaanxi Haitian Pharmaceutical's Four Seasons Antiviral Blend, Zaozhuang Sanjiu's Cold Spirit Granules, and Sichuan Good Doctor's Anti-Susceptibility Granules, increased sales by more than 100% at the terminal of China's online pharmacies.
-
State Administration for Market Regulation: Implement the real-name system for online sales of prescription drugs
Time of Update: 2022-09-06
According to the website of the State Administration for Market Regulation, recently, the State Administration for Market Regulation issued the "Measures for the Supervision and Administration of Drug Online Sales" (Order No. 58 of the State Administration for Market Regulation), which will come into force on December 1, 2022 .
-
Collects large varieties of omeprazole enteric-coated tablets, which are converted from prescription drugs to over-the-counter drugs
Time of Update: 2022-09-06
The announcement states: According to the provisions of the Measures for the Classification and Administration of Prescription Drugs and Over-the-Counter Drugs (Trial Implementation) (formerly Order No. 10 of the State Drug Administration), after the State Drug Administration organized demonstration and review, omeprazole enteric-coated tablets were converted from prescription drugs to over-the-counter drugs.
-
In the third quarter, can the high prosperity of the pharmaceutical and biological industry continue?
Time of Update: 2022-09-06
Among the A-share pharmaceutical and biological companies that have disclosed their semi-annual reports in the first half of the year, more than half of the net profit attributable to the parent company achieved a year-on-year increase, which shows that the overall prosperity of the industry is still relatively high .
-
I have been vaccinated with the bivalent and quadrivalent HPV vaccine, can I re-vaccinate the 9-valent HPV vaccine?
Time of Update: 2022-09-06
Bi Hui pointed out that women First, in terms of protective effect, the nine-valent HPV vaccine can prevent about 92% of cervical cancers, and the protective power of the bivalent and quadrivalent HPV vaccines is also more than 70%.
-
How did the local pharmaceutical company's PD-1 product perform after it was launched?
Time of Update: 2022-09-06
On August 23, Kangfang Bio released its interim results: the company's world-first new PD-1/CTLA-4 dual-antibody drug (Cadonilimumab Injection, trade name: Ketanil®) was successfully approved for marketing.
On August 23, Kangfang Bio released its interim results: the company's world-first new PD-1/CTLA-4 dual-antibody drug (Cadonilimumab Injection, trade name: Ketanil®) was successfully approved for marketing.
-
The enthusiasm for IPO of pharmaceutical companies is still high, and the Science and Technology Innovation Board welcomes another medical company to go public
Time of Update: 2022-08-30
On August 18, United Imaging Medical announced that the company's shares will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on August 22, 2022 .
